Thromboembolic disorders and helicobacter pylori: 616.151.511:616-008.6:616-092/085

Abstract

Introduction. Helicobacter pylori is the most common human infection; the level of its prevalence in developing countries is
incomparably higher than prevalence rates in developed countries. In 1983 it was found that bacteria can penetrate into gastric mucosa. Later more than 50 cases were described of extradigestive manifestations of H. pylori associated with development of diseases related to cardiology, dermatology, endocrinology, obstetrics and gynecology, hematology, pulmonology,
neurology, dentistry, ophthalmology, otolaryngology and pediatrics.

The aim was to study the role of H. pylori infection in the pathogenesis of thrombotic disorders.

Materials and methods. We examined 150 patients with deep vein thrombosis of lower extremities, pulmonary embolism,
ischemic stroke and other thrombogenic states that had the most common types of genetic polymorphisms of thrombotic
genes: MTRR — 19%, MTHFR — 10%, GpIa (heterozygous variant) — 11%. More than 60% of patients with thromboembolic disorders had a positive test for H. pylori IgG. The main approach for prophylaxis and treatment of thromboembolic disorders
associated with H. pylori was the appointment of drugs that are effective in the eradication of these bacteria together with
obligatory anticoagulant, antiaggregant and vascular tropic therapy. Recuperation from H. pylori in patients with thrombotic
disorders was fixed by respiratory test or by determination of H. pylori IgG.

Results. 7-year monitoring of patients with almost total recanalization of thromboses (patients with thromboses of lower extremities) during anticoagulative therapy and also effectively treated from H. pylori, did not reveal any recurrences of thromboembolic disorders. Among all 48 patients thrombosis recurrence was observed in 1 case.

Conclusion. It can be supposeed that H. pylori are capable to induce and maintain thrombotic disorders in patients with both
hereditary and acquired forms of thrombophilias.

References

1. Pounder R. E., Ng D. The prevalence of Helicobacter pylori infection in different countries. Aliment Pharmacol Ther. 1995; 9 (Suppl 2): 33–9.
2. Warren J. R., Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet. 1983; 1 (8336): 1273–5.
3. Bardakhchyan E. A., Lomov S. Yu., Kharlanov N. G., Kamneva N. V. The role of Helicobacter pylori in the development of extrastastroduodenal diseases [Helicobacter pylori pri razvitii ekstragastroduodenal’nyh zabolevanij]. Eksperimental’naya i klinicheskaya gastroehnterologiya. 2005; 3: 20–7 (in Russ.).
4. Fadeyenko G. D. Helicobacter pylori and extra-gastric manifestations [Helicobacter pylori i vnegastral’nye proyavleniya]. Ukraїns’kij terapevtichnij zhurnal. 2004; 2: 95–9 (in Russ.).
5. Zimmerman Ya. S. Helicobacter pylori — infection: extragastric effects and diseases (critical analysis) [Helicobacter pylori — infekciya: vnezheludochnye effekty i zabolevaniya (kriticheskij analiz)]. Klinicheskaya medicina. 2006; 4: 63–7 (in Russ.).
6. Vasiliev S. A., Vinogradov V. L., Gemjyan E. G. Helicobacter pylori in the pathogenesis, diagnosis and treatment of idiopathic thrombocytopenic purpura [Helicobacter pylori v patogeneze, diagnostike i lechenii idiopaticheskoj trombocitopenicheskoj purpury]. Tromboz, gemostaz i reologiya. 2008; 4: 10–7 (in Russ.).
7. Vasiliev S. A., Vinogradov V. L., Gemjyan E. G. et al. Results of treatment of patients with idiopathic thrombocytopenic purpura infected with Helicobacter pylori [Rezul’taty lecheniya bol’nyh idiopaticheskoj trombocitopenicheskoj purpuroj, inficirovannyh Helicobacter pylori]. Tromboz, gemostaz i reologiya. 2011; 3: 24–8 (in Russ.).
8. Gasbarrini A., Franceschi F., Armuzzi A. et al. Extradigestive manifestations of Helicobacter pylori gastric infection. Gut. 1999; 45 (Suppl 1): 112–9.
9. Realdi G., Dore M. P., Fastame L. Extradigestive manifestations of Helicobacter pylori infection: fact and fiction. Dig Dis Sci. 1999; 44 (2): 229–36.
10. De Koster E., De Bruyne I., Langlet P., Deltenre M. Evidence based medicine and extradigestive manifestations of Helicobacter pylori. Acta Gastroenterol Belg. 2000; 63 (4): 388–92.
11. Sherman P. M., Lin F. Y. Extradigestive manifestation of Helicobacter pylori infection in children and adolescents. Can J Gastroenterol. 2005; 19 (7): 421–4.
12. Baudron C. R., Franceschi F., Salles N., Gasbarrini A. Extragastric diseases and Helicobacter pylori. Helicobacter. 2013; 18 (Suppl 1): 44–51.
13. Pacifico L., Osborn J. F., Tromba V. et al. Helicobacter pylori infection and extragastric disorders in children: a critical update. World J Gastroenterol. 2014; 20 (6): 1379–401.
14. Dufour C., Brisigotti M., Fabretti G. et al. Helicobacter pylori gastric infection and sideropenic refractory anemia. J Pediatr Gastroenterol Nutr. 1993; 17: 225–7.
15. Muhsen K., Cohen D. Helicobacter pylori infection and iron stores: a systematic review and meta-analysis. Helicobacter. 2008; 13 (5): 323–40.
16. Vasiliev S. A., Vinogradov V. L., Smirnov A. N. Thrombosis and thrombophilia: classification, diagnosis, treatment, prevention [Trombozy i trombofilii: klassifikaciya, diagnostika, lechenie, profilaktika]. Russkij medicinskij zhurnal. 2013; 17: 896–901 (in Russ.).
17. Vasiliev S. A., Vinogradov V. L., Gemjyan E. G. The experience of outpatient treatment of patients with thrombosis and thrombophilia [Opyt ambulatornogo lecheniya bol’nyh s trombozami i trombofiliyami]. Terapevticheskij arhiv. 2013; 85 (12): 47–50 (in Russ.).
18. Vasiliev S. A., Vinogradov V. L., Gemjyan E. G. The problem of hemorrhagic syndrome in the treatment of antagonists of vitamin K [Problema gemorragicheskogo sindroma pri lechenii antagonistami vitamina K]. Terapevticheskij arhiv. 2012; 84 (7): 89–94 (in Russ.).
19. Vorobiev A. I., Vasilyev S. A., Gorodetsky V. M. Hypercoagulability syndrome: classification, pathogenesis, diagnostics, therapy [Giperkoagulyacionnyj sindrom: klassifikaciya, patogenez, diagnostika, terapiya]. Gematologiya i transfuziologiya. 2016; 61 (3): 116–22 (in Russ.).
20. Urnova E. S., Pokrovskaya O. S., Gracheva M. A. Hypercoagulable syndrome with multiple myeloma [Giperkoagulyacionnyj sindrom pri mnozhestvennoj mielome]. Terapevticheskij arhiv. 2014; 86 (7): 73–9 (in Russ.).
21. Panteleev M. A., Vasilyev S. A., Sinauridze E. I. et al. Practical coagulology. [Prakticheskaya koagulologiya (Pod red. akad. A. I. Vorob’eva)]. Moskva: Prakticheskaya medicina. 2011: 192 s (in Russ.).
22. Vasilyev S. A., Vinogradov V. L., Shutov S. A., Markova M. L. TAFI is an anti-fibrinolytic and anti-inflammatory factor [TAFI — antifibrinoliticheskij i protivovospalitel’nyj factor]. Tromboz, gemostaz i reologiya. 2014; 4: 12–7 (in Russ.).
23. Hershko C., Hoffbrand A. V., Keret D. et al. Role of autoimmune gastritis, Helicobacter pylori and celiac disease in refractory or unexplained iron deficiency anemia. Haematologica. 2005; 90 (5): 585–95.
24. Emiralioglu N., Yenicesu I., Sari S. et al. An insight into the relationships between prohepcidin, iron deficiency anemia, and interleukin-6 values in pediatric Helicobacter pylori gastritis. Eur J Pediatr. 2015; 174 (7): 903–10.
25. Hooshmand B., Solomon A., Kareholt I. et al. Homocysteine and holotranscobalamin and the risk of Alzheimer disease: a longitudinal study. Neurology. 2010; 75: 1408–14.
26. Werder S. F. Cobalamin deficiency, hyperhomocysteinemia, and dementia. Neuropsychiatr Dis Treat. 2010; 6: 159–95.
27. Kaptan K., Beyan C. Does hyperhomocysteinemia due to vitamin B 12 deficiency associated with Helicobacter pylori infection has a role on cerebral stroke? Med Sci Monit. 2002; 8: LE52-LE53.
28. Andrеs E., Kurtz J. E. Pulmonary embolism in pernicious anemia and hyperhomocysteinemia. Chest. 2003; 124 (3): 1181.
29. Whincup P. H., Mendall M. A., Perry I. J., Strachan D. P. Hyperhomocysteinaemia, Helicobacter pylori, and coronary heart disease. Heart. 1997; 78 (5): 524.
30. Kaptan K., Beyan C., Ural A. U. et al. Helicobacter pylori — is it a novel causative agent in Vitamin B12 deficiency? Arch Intern Med. 2000; 160 (9): 1349–53.
31. Bai Y., Wang Z., Bai X. et al. Cross-reaction of antibody against Helicobacter pylori urease B with platelet glycoprotein IIIa and its significance in the pathogenesis of immune thrombocytopenic purpura. Int J Hematol. 2009; 89: 142–9.
32. Arnold D. M., Bernotas A., Nazi I. et al. Platelet count response to H. pylori treatment in patients with immune thrombocytopenic purpura with and without H. pylori infection: a systematic review. Haematologica. 2009; 94 (6): 850–6.
33. Gupta V., Eden A. J., Mills M. J. Helicobacter pylori and autoimmune neutropenia. Clin Lab Haematol. 2002; 24 (3): 183–5.
34. Papadaki H. A., Pontikoglou C., Stavroulaki E. et al. High prevalence of Helicobacter pylori infection and monoclonal gammopathy of undetermined significance in patients with chronic idiopathic neutropenia. Ann Hematol. 2005; 84: 317–20.
35. Kudryavtseva L. V., Isakov V. A., Ivannikov I. O. Resistance of Helicobacter pylori to metronidazole, clarithromycin and amoxicillin in Moscow, St. Petersburg and Abakan in 2001 [Rezistentnost’ Helicobacter pylori k metronidazolu, klaritromicinu i amoksicillinu v Moskve, Sankt-Peterburge i Abakane v 2001]. Pediatriya. 2002; 2 (pril.): 61–3 (in Russ.).
36. Malfertheiner P., Megraud F., O’Morain C. A. et al. Management of Helicobacter pylori infection — the Maastricht IV/ Florence Consensus Report. Gut. 2012; 61 (5): 646–64.
37. Cicconi V., Carloni E., Franceschi F. et al. Disappearance of antiphospholipid antibodies syndrome after Helicobacter pylori eradication. Am J Med. 2001; 111 (2): 163–4.
38. Reinauer S., Megahed M., Goerz G. et al. Schönlein-Henoch purpura associated with gastric Helicobacter pylori infection. J Am Acad Dermatol. 1995; 33 (5 Pt 2); 876–9.
39. Cecchi R., Torelli E. Schönlein-Henoch purpura in association with duodenal ulcer and gastric Helicobacter pylori infection. J Dermatol. 1998; 25 (7): 482–4.
40. Frederiksen H., Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood. 1999; 94 (3): 909–13.
41. Tohda S., Ohkusa T. Resolution of refractory idiopathic thrombocytopenic purpura after eradication of Helicobacter pylori. Am J Hematol. 2000; 65: 329–30.
42. Malik A. A., Ganti A. K., Potti A. et al. Role of Helicobacter pylori infection in the incidence and clinical course of monoclonal gammopathy of undetermined significance. Am J Gastroenterol. 2002; 97 (6): 1371–4.
43. Annibale B., Marignani M., Monarca B. et al. Reversal of iron deficiency anemia after Helicobacter pylori eradication in patients with asymptomatic gastritis. Ann Intern Med. 1999; 131 (9): 668–72.
44. Marino M. C., de Oliveira C. A., Rocha A. M. et al. Long-term effect of Helicobacter pylori eradication on plasma homocysteine in elderly patients with cobalamin deficiency. Gut. 2007; 56 (4): 469–74.
45. Rajkumar S. V., Kyle R. A., Plevak M. F. et al. Helicobacter pylori infection and monoclonal gammopathy of undetermined significance. Br J Haematol. 2002; 119: 706–8.
46. Campuzano-Maya G. Hematologic manifestations of Helicobacter pylori infection. World J Gastroenterol. 2014; 20 (36): 12 818–38.
47. Cotticelli L., Borrelli M., D’Alessio A. C. et al. Central serous chorioretinopathy and Helicobacter pylori. Eur J Ophthalmol. 2006; 16 (2): 274–8.